These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24903735)

  • 1. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
    Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Xu H; Wu Y; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Oct; 85():359-70. PubMed ID: 25105924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo Evaluation of 17-phenylpropylamine/phenoxyethylamine- 17-demethoxygeldanamycins as Potent Hsp90 Inhibitors.
    Li Z; Jia L; Xu H; Lu C; Shena Y
    Med Chem; 2015; 11(5):482-8. PubMed ID: 25537129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
    Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS
    Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
    J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
    Shen G; Wang M; Welch TR; Blagg BS
    J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
    J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
    Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
    Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
    Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of heat-shock protein 90 inhibitors: geldanamycin derivatives with broad antiviral activities.
    Li YP; Shan GZ; Peng ZG; Zhu JH; Meng S; Zhang T; Gao LY; Tao PZ; Gao RM; Li YH; Jiang JD; Li ZR
    Antivir Chem Chemother; 2010 Aug; 20(6):259-68. PubMed ID: 20710066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New, non-quinone fluorogeldanamycin derivatives strongly inhibit Hsp90.
    Hermane J; Bułyszko I; Eichner S; Sasse F; Collisi W; Poso A; Schax E; Walter JG; Scheper T; Kock K; Herrmann C; Aliuos P; Reuter G; Zeilinger C; Kirschning A
    Chembiochem; 2015 Jan; 16(2):302-11. PubMed ID: 25572106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.
    Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 90: inhibitors in clinical trials.
    Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
    J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.